Inclusion Criteria:

Patients with liver cirrhosis with the 1 year risk of HCC of 5% or higher meeting all of
following criteria;

1. The evidence of cirrhosis of any etiology within 12 months prior to screening
Definition of cirrhosis by any of following methods

- 1) Histologically by liver biopsy;

- 2) Non-histologically by evidence of portal hypertension in the presence of
chronic liver disease;

- Evidence of portal hypertension, including any of followings;

1. The identification of splenomegaly on USG, CT, or MRI examinations
with typical features of cirrhosis

2. The identification of esophageal or gastric varices on endoscopic
examination

2. High Risk Index (>=2.33); Risk Index = 1.65 (if the prothrombin activity is <=75%) +
1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is
<=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus [HCV] or hepatitis
B surface antigen [HBsAg] is positive).

3. Older than 20 years of age

4. Absence of previous or current history of HCC

5. Absence of HCC should be identified by liver USG, dynamic CT, or contrast-enhanced
MRI within 6 months prior to screening

6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2

7. Patient is able to comply with scheduled visits, evaluation plans, and other study
procedures.

8. Patient is willing to provide written informed consent

Exclusion Criteria:

Presence of any of following criteria;

1. Active or suspected cancer other than HCC, or a history of malignancy where the risk
of recurrence is >20% within 2 years

2. Significant medical comorbidities in which survival is predicted to be less than 3
years

3. Estimated glomerular filtration rate (GFR) < 30 mL/min/1.73m2

4. Precautions for MRI (cardiac pacemaker, ferromagnetic implants, etc.)

5. Severe claustrophobia that may interfere with protocol compliance.

6. Any other condition which, in the opinion of the Investigator, would make the patient
unsuitable for enrollment or could interfere with the completing the study.